Clinical Trial VICCTHN1340


A Phase II Study of Carboplatin, Nab-Paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Principal Investigator(s)

Jill Gilbert


  • Protocol No. VICCTHN1340
  • Open Date: 10/14/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: Estimate the overall objective response rate (CR+PR) after induction chemotherapy with nab-paclitaxel, carboplatin and cetuximab in patients with unresectable and/or >/= N2b locally advanced SCCHN who are considered appropriate candidates for an induction approach.
  • Disease Sites: Head/Neck
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Carboplatin; Cetuximab; Cetuximab (Erbitux); Nab-paclitaxel
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01412229
  • Secondary Protocol No: LCCC 1103



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.